The global electrochemical-based biosensors market was valued at US$7.32 billion in 2024 and is projected to reach US$16.45 billion by 2032, growing at a CAGR of 10.6% from 2025 to 2032. The U.S. holds a 35% global revenue share, while China is expected to grow at a CAGR exceeding 9%. These biosensors, which use potentiometric, amperometric, and conductometric techniques, are widely used in glucose monitoring, pathogen detection, and environmental analysis due to their sensitivity, portability, and cost-effectiveness. Key drivers include rising chronic disease prevalence, advancements in wearable technology, and increased adoption in point-of-care testing (POCT), especially in diabetes and infectious disease management. Continuous glucose monitoring systems accounted for over 40% of market revenue in 2024. The pandemic accelerated development of rapid biosensor tests with detection times under five minutes. Breakthroughs in nanotechnology—such as graphene, carbon nanotubes, and MXenes—have improved detection limits by up to 1,000 times and enabled miniaturization. Over 150 global patents were filed in 2024 for novel nanocomposite designs. Enzyme immobilization techniques have extended biosensor lifespans to several months. Emerging applications include detection of neurodegenerative biomarkers (Alzheimer’s, Parkinson’s) and multidrug-resistant pathogens. Developing nations, particularly China and India, are poised for significant growth, with local manufacturers offering low-cost alternatives (60–70% cheaper than premium brands). Government initiatives like India’s National Biopharma Mission are supporting domestic R&D. The pharmaceutical industry is increasingly adopting biosensors for real-time metabolic monitoring in clinical trials. Artificial intelligence enhances accuracy by compensating for signal drift and improving measurement precision by up to 40% in diabetic patients. Cloud-connected networks enable population-level health monitoring and preventive care models. The market is segmented by type, application, and end user, with major players including Roche Diagnostics, Abbott Laboratories, Bayer AG, Medtronic, I-SENS, Inc., Eversense, Siemens Healthcare, Conductive Technologies, LifeScan, Nova Biomedical, ACON Laboratories, and Universal Biosensors.

Kyndryl has entered into a strategic partnership with Nova Intelligence, a leader in multi-agent AI solutions for SAP Clean Core modernisation, to accelerate AI-driven SAP digital transformation projects. The collaboration combines Kyndryl’s SAP modernisation and data transformation services with Nova Intelligence’s agentic AI capabilities to help enterprise customers migrate to and modernise SAP Cloud ERP systems, aligning them with SAP Clean Core principles. The partnership enables faster, more cost-effective transformation by automating custom code documentation, analysis, and modernisation, reducing risk and supporting business continuity. Both companies have leveraged the technology to improve internal SAP applications, with Kyndryl using Nova Intelligence’s AI agents to modernise two mission-critical legacy SAP applications, reducing manual work and costs.

North Lanarkshire Council has approved a 30MW/60MWh lithium-ion battery energy storage system (BESS) to be developed by Renewable Connections at a site on Burnbank Street in Coatbridge. The system will connect to SP Energy Networks Coatbridge and is expected to support the council's net zero by 2030 target, optimize renewable energy integration across the UK, and improve grid stability. Construction is scheduled to begin in 2026, with the project operational for up to 40 years. The approval follows previous project consents in Scotland and aligns with broader UK efforts to integrate low-carbon technologies, which National Grid estimates could save the energy system up to £40 billion by 2025.

The article discusses a comprehensive market report on the Smart Wearable Glucose Patch Market (2025-2032) by Coherent Market Insights, analyzing trends, drivers, competitive landscape, and key players. It highlights market growth, technological innovation, and strategic initiatives by companies like Abbott Laboratories, Dexcom Inc., and Medtronic plc.

The National Agency on Corruption Prevention (NACP) added the owner of AliExpress, AliExpress Russia Holding Private Ltd, to the list of international sponsors of the war. The company continues operating in Russia, selling foreign goods. Alibaba.KOM (RU) LLC reported 16.3 billion rubles in 2022 profits. Quzhou Nova purchased copper alloy from a Russian-controlled plant via Alibaba platforms. The NACP oversees compliance, integrity checks, and audits, aligning with OECD standards.